#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Kirsten Harting Email
Chief Medical Officer (CMO) . Alzinova AB
Mölndal,
LocationPrimary Email
How to contact Kirsten Harting
Join and see Kirsten's contact info for free!Current Roles
Employees:
12Revenue:
$1.9MAbout
Alzinova AB is a Swedish biopharma company specializing in the treatment of Alzheimer's disease by targeting neurotoxic amyloid-β oligomers. The lead candidate, ALZ-101, is in late preclinical development as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that target the toxic amyloid-β oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201, in early preclinical development, was generated with the AβCC peptide™ technology and the ambition is to expand the pipeline further. The Company's Certified Advisor on Nasdaq First North is Corpura Fondkommission AB, info@corpura.se, +46 (0)768-532 822.Alzinova AB Address
Pepparedsleden 1Mölndal, null